<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND AIMS: Gender differences in the prognosis of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) remain controversial </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this study was to complete a comprehensive analysis of gender differences in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> survival derived from population registries in Taiwan </plain></SENT>
<SENT sid="2" pm="."><plain>MATERIALS AND METHODS: We analyzed survival data for patients diagnosed with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> between 1998 and 2005 derived from the Taiwan <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Registry database </plain></SENT>
<SENT sid="3" pm="."><plain>During this time period, 65,113 patients were registered, and 62,060 patients were eligible </plain></SENT>
<SENT sid="4" pm="."><plain>Gender differences in overall survival and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-specific survival were analyzed by use of the Kaplan-Meier method </plain></SENT>
<SENT sid="5" pm="."><plain>We then modeled the risk in different genders by use of a multivariate proportional hazard (Cox) model adjusting for possible confounders of survival </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: The 5-year period overall and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-specific survivals were significantly higher in women than in men [51.84 % (95 % confidence interval (CI), 51.22-52.46) vs. 47.68 % (95 % CI, 47.14-48.22), log-rank p &lt; 0.001; and 56.44 % (95 % CI, 55.82-57.07) vs. 53.47 % (95 % CI, 52.92-54.01), log-rank p &lt; 0.001, respectively] </plain></SENT>
<SENT sid="7" pm="."><plain>Subgroup analysis revealed higher overall and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-specific survivals in women between 50 and 80 years age and those with <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> (p &lt; 0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>By use of Cox modeling, we noted a decreased hazard ratio (HR) for <z:hpo ids='HP_0011420'>death</z:hpo> from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> in women compared with men (HR, 0.820-0.971), especially in the 50-80-year age group </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> estimated HRs, after adjusting for age, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> histology, and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> site, had significant trends of a decreasing risk of <z:hpo ids='HP_0011420'>death</z:hpo> from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> in women </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Our findings suggest that overall and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-specific survival advantage was most evident in women between 50 and 80 years of age </plain></SENT>
</text></document>